Literature DB >> 12220686

The role of antibodies in myasthenia gravis.

M De Baets1, M H W Stassen.   

Abstract

Myasthenia gravis is an autoimmune disease associated with antibodies directed to the postsynaptic acetylcholine receptor. These antibodies reduce the number of receptors. Autoantibodies against AChR and other muscle antigens can be used for the diagnosis of myasthenia gravis and related disorders. The origin and the role of these antibodies in the disease are discussed. Experimental autoimmune myasthenia gravis, an experimental model closely mimicking the disease, has provided answers to many questions about the role of antibodies, complement macrophages and AChR anchor proteins. Genetically modified anti-AChR antibodies may also be used in the future to treat myasthenia. Copyright 2002 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12220686     DOI: 10.1016/s0022-510x(02)00200-9

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  13 in total

1.  Pleiotropic effects of the 8.1 HLA haplotype in patients with autoimmune myasthenia gravis and thymus hyperplasia.

Authors:  Claire Vandiedonck; Geneviève Beaurain; Matthieu Giraud; Catherine Hue-Beauvais; Bruno Eymard; Christine Tranchant; Philippe Gajdos; Jean Dausset; Henri-Jean Garchon
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-15       Impact factor: 11.205

Review 2.  [Plasma exchange as a therapeutic option in neurological disorders].

Authors:  H C Lehmann; H P Hartung; G R Hetzel; B C Kieseier
Journal:  Nervenarzt       Date:  2007-02       Impact factor: 1.214

3.  Overexpression of rapsyn in rat muscle increases acetylcholine receptor levels in chronic experimental autoimmune myasthenia gravis.

Authors:  Pilar Martínez-Martínez; Mario Losen; Hans Duimel; Peter Frederik; Frank Spaans; Peter Molenaar; Angela Vincent; Marc H De Baets
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

4.  Selection of a human butyrylcholinesterase-like antibody single-chain variable fragment resistant to AChE inhibitors from a phage library expressed in E. coli.

Authors:  Adriano Podestà; Serena Rossi; Ilaria Massarelli; Sara Carpi; Barbara Adinolfi; Stefano Fogli; Anna Maria Bianucci; Paola Nieri
Journal:  MAbs       Date:  2014 Jul-Aug       Impact factor: 5.857

5.  The high frequency and clinical feature of seronegative myasthenia gravis in Southern China.

Authors:  Hui-Yu Feng; Hai-Yan Wang; Wei-Bin Liu; Xue-Tao He; Xin Huang; Chuan-Ming Luo; Yan Li
Journal:  Neurol Sci       Date:  2012-07-25       Impact factor: 3.307

6.  Both binding and blocking antibodies correlate with disease severity in myasthenia gravis.

Authors:  Sa-Yoon Kang; Jung-Hwan Oh; Sook Keun Song; Jung Seok Lee; Jay Chol Choi; Ji-Hoon Kang
Journal:  Neurol Sci       Date:  2015-05-12       Impact factor: 3.307

7.  The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice.

Authors:  B P Morgan; J Chamberlain-Banoub; J W Neal; W Song; M Mizuno; C L Harris
Journal:  Clin Exp Immunol       Date:  2006-11       Impact factor: 4.330

8.  Acetylcholine receptor-alpha subunit expression in myasthenia gravis: a role for the autoantigen in pathogenesis?

Authors:  Jian Rong Sheng; Liang Cheng Li; Bellur S Prabhakar; Matthew N Meriggioli
Journal:  Muscle Nerve       Date:  2009-08       Impact factor: 3.217

9.  High avidity anti-beta 2-glycoprotein I antibodies in patients with antiphospholipid syndrome.

Authors:  S Cucnik; T Kveder; I Krizaj; B Rozman; B Bozic
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

10.  Toxicogenomics of subchronic hexachlorobenzene exposure in Brown Norway rats.

Authors:  Janine Ezendam; Frank Staedtler; Jeroen Pennings; Rob J Vandebriel; Raymond Pieters; Johannes H Harleman; Joseph G Vos
Journal:  Environ Health Perspect       Date:  2004-05       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.